NCT06890611View on ClinicalTrials.gov

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

September 26, 2025

Study Completion Date

September 26, 2025

Conditions

Healthy

Interventions

DRUG

Bimagrumab

Administered SC

DRUG

Tirzepatide

Administered SC

DRUG

Bimagrumab + Tirzepatide Coformulation

Administered SC

Trial Locations (1)

75247

Fortrea Clinical Research Unit, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06890611 - A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants | Biotech Hunter | Biotech Hunter